I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

Published on January 6, 2025

in CD73-high NSCLC patients. As a result, further clinical investment in uliledlimab will be put on hold. The Company will continue to

Continue reading on website
Other news

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

January 6, 2025
risk that Achieve may not be able to obtain additional financing to fund the development and commercialization of cytisinicline; the risk

Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

January 6, 2025
Partner of String Capital Management Co., Limited since 2018. Previously he was the Head of Private Equity Investment and Fund of Funds